

Sanjay K Murthy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2456156/publications.pdf>

Version: 2024-02-01

46
papers

1,201
citations

471061

17
h-index

414034

32
g-index

49
all docs

49
docs citations

49
times ranked

1489
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Surgery and the Subtype of Inflammatory Bowel Disease Impact the Risk of Venous Thromboembolism After Hospital Discharge. <i>Digestive Diseases and Sciences</i> , 2022, 67, 2471-2479. | 1.1 | 9 |
| 2 | Association Between Endoscopist Specialty and Colonoscopy Quality: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1931-1946. | 2.4 | 12 |
| 3 | Earlier Anti-TNF Initiation Leads to Long-term Lower Health Care Utilization in Crohn's Disease but Not in Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2607-2618.e14. | 2.4 | 13 |
| 4 | Variation in care of patients with elderly-onset inflammatory bowel disease in Ontario, Canada: A population-based cohort study. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, e16-e30. | 0.1 | 10 |
| 5 | Crohn's and Colitis Canada's 2021 Impact of COVID-19 & Inflammatory Bowel Disease in Canada: A Knowledge Translation Strategy. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, S10-S19. | 0.1 | 2 |
| 6 | Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Seniors With IBD. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, S34-S39. | 0.1 | 2 |
| 7 | OUP accepted manuscript. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, S20-S26. | 0.1 | 0 |
| 8 | OUP accepted manuscript. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, S40-S45. | 0.1 | 4 |
| 9 | Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Health Care Delivery During the Pandemic and the Future Model of Inflammatory Bowel Disease Care. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, S61-S67. | 0.1 | 7 |
| 10 | OUP accepted manuscript. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, S1-S9. | 0.1 | 5 |
| 11 | OUP accepted manuscript. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, S27-S33. | 0.1 | 3 |
| 12 | Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: COVID-19 Vaccines' Biology, Current Evidence and Recommendations. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, S54-S60. | 0.1 | 9 |
| 13 | Trends in Corticosteroid Use During the Era of Biologic Therapy: A Population-Based Analysis. <i>American Journal of Gastroenterology</i> , 2021, 116, 1284-1293. | 0.2 | 12 |
| 14 | Shifting Health Care Use from Hospitalisations and Surgeries to Outpatient Visits in Children with Inflammatory Bowel Disease: A Population-based Cohort Study from Ontario, Canada. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1991-2000. | 0.6 | 10 |
| 15 | Home parenteral nutrition patients on mixed oil lipid emulsion have a higher rate of hospitalizations compare to those on soybean oil' a prospective 2-year cohort study. <i>Clinical Nutrition</i> , 2021, 40, 4616-4623. | 2.3 | 1 |
| 16 | AGA Clinical Practice Update on Endoscopic Surveillance and Management of Colorectal Dysplasia in Inflammatory Bowel Diseases: Expert Review. <i>Gastroenterology</i> , 2021, 161, 1043-1051.e4. | 0.6 | 102 |
| 17 | Multivariable models for advanced colorectal neoplasms in screen-eligible individuals at low-to-moderate risk of colorectal cancer: towards improving colonoscopy prioritization. <i>BMC Gastroenterology</i> , 2021, 21, 383. | 0.8 | 0 |
| 18 | Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study. <i>Gut</i> , 2020, 69, 274-282. | 6.1 | 145 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Absence of Day 3 Steroid Response Predicts Colitis-Related Complications and Colectomy in Hospitalized Ulcerative Colitis Patients. <i>Journal of the Canadian Association of Gastroenterology</i> , 2020, 3, 169-176. | 0.1 | 2 |
| 20 | Tumor Necrosis Factor Inhibitors May Have Limited Efficacy for Complex Perianal Fistulas Without Luminal Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2020, 65, 1784-1789. | 1.1 | 6 |
| 21 | Longitudinal Trends in the Direct Costs and Health Care Utilization Ascribable to Inflammatory Bowel Disease in the Biologic Era: Results From a Canadian Population-Based Analysis. <i>American Journal of Gastroenterology</i> , 2020, 115, 128-137. | 0.2 | 39 |
| 22 | Venous thromboembolic events in inflammatory bowel diseases: A review of current evidence and guidance on risk in the post-hospitalization setting. <i>Thrombosis Research</i> , 2020, 194, 26-32. | 0.8 | 8 |
| 23 | Providing Hospitalized Ulcerative Colitis Patients With Practice Guidelines Improves Patient-Reported Outcomes. <i>Journal of the Canadian Association of Gastroenterology</i> , 2020, 4, 131-136. | 0.1 | 4 |
| 24 | Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1354-1363. | 0.6 | 38 |
| 25 | Risk of Venous Thromboembolism After Hospital Discharge in Patients With Inflammatory Bowel Disease: A Population-based Study. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1761-1768. | 0.9 | 35 |
| 26 | Vedolizumab treatment across antiretroviral treatment interruption in chronic HIV infection: the HAVARTI protocol for a pilot dose-ranging clinical trial to assess safety, tolerance, immunological and virological activity. <i>BMJ Open</i> , 2020, 10, e041359. | 0.8 | 0 |
| 27 | Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn's Disease: The Toronto Consensus. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1-13. | 0.9 | 73 |
| 28 | Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1680-1713. | 2.4 | 32 |
| 29 | Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease. <i>Journal of the Canadian Association of Gastroenterology</i> , 2019, 2, e1-e34. | 0.1 | 32 |
| 30 | Predictive models of disease burden at diagnosis in persons with adult-onset ulcerative colitis using health administrative data. <i>BMC Gastroenterology</i> , 2019, 19, 13. | 0.8 | 2 |
| 31 | The Effect of Initiation of Anti-TNF Therapy on the Subsequent Direct Health Care Costs of Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1718-1728. | 0.9 | 31 |
| 32 | The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization. <i>Journal of the Canadian Association of Gastroenterology</i> , 2019, 2, S17-S33. | 0.1 | 63 |
| 33 | Health Care Utilization and Costs for Patients With End-Stage Liver Disease Are Significantly Higher at the End of Life Compared to Those of Other Decedents. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2339-2346.e1. | 2.4 | 24 |
| 34 | Past and Future Burden of Inflammatory Bowel Diseases Based on Modeling of Population-Based Data. <i>Gastroenterology</i> , 2019, 156, 1345-1353.e4. | 0.6 | 273 |
| 35 | Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1788-1798.e2. | 2.4 | 23 |
| 36 | Appropriateness of Biologics in the Management of Crohn's Disease Using RAND/UCLA Appropriateness Methodology. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 328-335. | 0.9 | 7 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | The Impact of Clostridium difficile Infection on Mortality in Patients With Inflammatory Bowel Disease. Journal of Clinical Gastroenterology, 2019, 53, 127-133. | 1.1 | 26 |
| 38 | Temporal trends in postcolonoscopy colorectal cancer rates in 50- to 74-year-old persons: a population-based study. Gastrointestinal Endoscopy, 2018, 87, 1324-1334.e4. | 0.5 | 17 |
| 39 | Rural and urban disparities in the care of Canadian patients with inflammatory bowel disease: a population-based study. Clinical Epidemiology, 2018, Volume 10, 1613-1626. | 1.5 | 48 |
| 40 | Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn's Disease: The Toronto Consensus. Journal of the Canadian Association of Gastroenterology, 2018, 1, 141-154. | 0.1 | 10 |
| 41 | Variable Endoscopist performance in proximal and distal adenoma detection during colonoscopy: a retrospective cohort study. BMC Gastroenterology, 2018, 18, 73. | 0.8 | 9 |
| 42 | Perspectives on endoscopic surveillance of dysplasia in inflammatory bowel disease: a survey of academic gastroenterologists. Endoscopy International Open, 2017, 05, E974-E979. | 0.9 | 15 |
| 43 | High end of life health care costs and hospitalization burden in inflammatory bowel disease patients: A population-based study. PLoS ONE, 2017, 12, e0177211. | 1.1 | 8 |
| 44 | Increased Risk of Venous Thromboembolic Events With Corticosteroid Versus Biologic Therapy for Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2016, 14, 166-167. | 2.4 | 2 |
| 45 | An Unusual Skin Manifestation in a Patient With Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2016, 14, A35-A36. | 2.4 | 3 |
| 46 | Extent of Early Clinical Response to Infliximab Predicts Long-term Treatment Success in Active Ulcerative Colitis. Inflammatory Bowel Diseases, 2015, 21, 2090-2096. | 0.9 | 25 |